Protocols frequently run for extended periods because tissue and anti-aging effects develop slowly
Hopefully, over the next few years, more drugs that have got really good evidence from trials are licensed and these issues become less of an issue in five to 10 years time.' An MHRA spokesperson told the Daily Mail: 'Retatrutide has not been approved for medicinal use in the UK
Semaglutide works for most patients when prescribed at the right dose, titrated correctly, and supported by clinical care that catches problems early
Here are some of the benefits we are seeing: Improved blood sugar control Increased insulin sensitivity Lowered risk of nerve damage and kidney disease (this is most pertinent for diabetic patients) Lowered cholesterol levels Lowered blood pressure levels Decreased risk of stroke Decreased risk of cardiac events (like a heart attack or heart disease) Its important to point out that most of these benefits are a result of losing weight (we see these benefits after bariatric surgery as well) but some studies are showing positive benefits on their own (regardless of the amount of weight loss)
Originally developed for type 2 diabetes, medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have produced substantial weight loss in clinical trials
However, these symptoms can have many causes, making professional evaluation important